Prolynx Revenue and Competitors

ProLynx (San Francisco, CA), founded in 2009 by Daniel V. Santi, M.D., Ph.D., and Gary W. Ashley, Ph.D., has developed advanced linker technologies and a facile, transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. ProLynx’s technology platform is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs – including peptides, proteins and small molecules -- using macromolecular and fixed supports (s.c. & i.v. injectables, implants, others). Unlike competing technologies – which depend on ester-cleaving linkers with half-lives of 12 to 24 hrs – we have “self-cleaving” chemical linkers that release the native drug with half-lives ranging from hours to months. We have applied this technology to three programs. A small molecule, SN38, which is a topoisomerase inhibitor, is linked to the inert matrix PEG through our programmable linkers. This PEG~SN38 (PLX038) is currently in Phase I clinical trials for solid tumors at the MD Anderson. We expect to complete this trial by the end of 2017. PLX039, is a subcutaneous, once monthly GLP1 receptor agonist. Here, the peptide is linked to the hydrogel matrix. The peptide is released from this depot with a half-life of a month. We are initiating GLP toxicity studies and expect to initiate Phase I clinical trials by the end of 2018. PLX040 is a subcutaneous, long-acting octreotide. Unlike sandostatin LAR, which is a deep intramuscular injection through an 18 gauge needle, PLX040 can be self-administered through a small-bore 27 - 29 gauge needle.